The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Blood Advances - Tập 1 - Trang 802-811 - 2017
Lucy C. Fox1,2, Katherine D. Cummins1,3, Ben Costello3,4, David Yeung5, Rebecca Cleary6, Cecily Forsyth7, Maciek Tatarczuch8, Kate Burbury8, Olga Motorna9, Jake Shortt9,10, Shaun Fleming3,10, Andrew McQuillan11, Anthony Schwarer1,2,12, Rosemary Harrup13, Amy Holmes14, Sumita Ratnasingam15, Kah-Lok Chan16, Wei-Hsun Hsu17, Asma Ashraf18, Faye Putt1
1Austin Hospital, Melbourne, Australia
2Epworth HealthCare, Melbourne, Australia
3Alfred Hospital, Melbourne, Australia
4Baker IDI Heart and Diabetes Institute, Melbourne, Australia
5Royal Adelaide Hospital, Adelaide, Australia
6Princess Alexandra Hospital, Brisbane, Australia
7Gosford Hospital, Gosford, Australia
8Peter MacCallum Cancer Centre, Melbourne, Australia
9Monash Health, Clayton, Melbourne, Australia;
10School of Clinical Sciences at Monash Health, Monash University, Clayton, Melbourne, Australia;
11Hollywood Medical Centre, Perth, Australia;
12Box Hill Hospital, Melbourne, Australia
13Royal Hobart Hospital, Hobart, Australia
14Canberra Hospital, Canberra, Australia
15Royal Melbourne Hospital, Melbourne, Australia
16St Vincent’s Hospital, Melbourne, Australia
17Royal Prince Alfred Hospital, Sydney, Australia
18Calvary Mater Hospital, Newcastle, Australia

Tóm tắt

Key PointsPrescribing appropriately for age and cardiovascular risk is likely to result in minimal permanent toxicity-related dasatinib cessation. CML patients on dasatinib with pleural effusion are more likely to have achieved MR4.5 after 6-month therapy than those without effusion.

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Blood Advances

Tập 1

802-811

Thông tin tác giả